| Name | Title | Contact Details |
|---|---|---|
Nick Crowe |
Chief Operating Officer | Profile |
Michelle Wong |
Chief Operating Officer | Profile |
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC).
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.
Brampton Cosmetic Surgery is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs